Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EBIT (2018 - 2025)

Neurogene's EBIT history spans 6 years, with the latest figure at -$27.5 million for Q4 2025.

  • For Q4 2025, EBIT fell 27.97% year-over-year to -$27.5 million; the TTM value through Dec 2025 reached -$103.3 million, down 25.09%, while the annual FY2025 figure was -$103.3 million, 25.09% down from the prior year.
  • EBIT reached -$27.5 million in Q4 2025 per NGNE's latest filing, down from -$23.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$12.6 million in Q2 2023 to a low of -$27.5 million in Q4 2025.
  • Average EBIT over 3 years is -$20.1 million, with a median of -$20.8 million recorded in 2024.
  • Peak YoY movement for EBIT: tumbled 59.84% in 2024, then dropped 7.29% in 2025.
  • A 3-year view of EBIT shows it stood at -$14.7 million in 2023, then plummeted by 46.01% to -$21.5 million in 2024, then dropped by 27.97% to -$27.5 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's EBIT are -$27.5 million (Q4 2025), -$23.8 million (Q3 2025), and -$26.1 million (Q2 2025).